Applied DNA Sciences, Inc. (NASDAQ:APDN) Short Interest Up 199.4% in December

Applied DNA Sciences, Inc. (NASDAQ:APDN) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 5,300,000 shares, an increase of 199.4% from the November 30th total of 1,770,000 shares. Based on an average trading volume of 5,810,000 shares, the short-interest ratio is presently 0.9 days.

Hedge Funds Weigh In On Applied DNA Sciences

An institutional investor recently bought a new position in Applied DNA Sciences stock. Jane Street Group LLC acquired a new position in shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 73,396 shares of the technology company’s stock, valued at approximately $48,000. Jane Street Group LLC owned approximately 0.24% of Applied DNA Sciences as of its most recent filing with the SEC. 22.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Applied DNA Sciences to a “sell” rating in a research note on Tuesday, September 17th.

Applied DNA Sciences Stock Up 0.7 %

Shares of NASDAQ:APDN opened at $0.18 on Friday. Applied DNA Sciences has a 52-week low of $0.12 and a 52-week high of $14.40. The business has a fifty day moving average of $0.20 and a two-hundred day moving average of $0.58. The stock has a market cap of $9.41 million, a P/E ratio of -0.02 and a beta of 0.46.

Applied DNA Sciences (NASDAQ:APDN) last issued its quarterly earnings data on Tuesday, December 17th. The technology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.01. Applied DNA Sciences had a negative net margin of 214.42% and a negative return on equity of 138.41%. On average, equities analysts anticipate that Applied DNA Sciences will post -1.8 earnings per share for the current year.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.